Replidyne, Inc. Cuts IPO To 4.5 Million Shares, $10 Each

WASHINGTON, June 28 (Reuters) - Biopharmaceutical company Replidyne Inc. on Wednesday cut its planned initial public offering to 4.5 million shares from 5 million and lowered the anticipated price to $10 each from between $14 and $16 each. The company filed an amended prospectus with the U.S. Securities and Exchange Commission, saying Merrill Lynch & Co., Morgan Stanley, Cowen and Co., and Pacific Growth Equities would underwrite the IPO.

Back to news